Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index," published in Nature Biotechnology, is the 2019 recipient of the
Following is a schedule of all Ionis presentations in Central European Time:
Monday, October 14, 2:45 p.m.– 3:00 p.m.'Cleavage of pre-mRNA in the Nucleus by RNase H1-dependent Antisense Oligonucleotides Causes RNA Polymerase II Transcription Termination' Tuesday, October 15, 10:20 a.m.– 10:35 a.m.'Development and Characterization of AZD8701, a High Affinity Antisense Oligonucleotide Targeting FOXP3 to Relieve Immunosuppression in Cancer' Tuesday, October 15, 11:25 a.m.– 11:45 a.m. Mary Ann Liebert, Inc.publishers Young Investigator Award, 'Antisense Oligonucleotides for the Treatment of Neurodegenerative Diseases' Tuesday, October 15, 11:45 a.m.– 12:05 p.m.Paper of the Year Award, 'Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index'
Sunday, October 13, 6:00 p.m.– 7:30 p.m.'Invalidation of GSK3B in the Pancreatic Beta Cell as a Therapeutic Target for T2D' Monday, October 14, 5:35 p.m.– 7:30 p.m.'Improved Safety & Tolerability Profile with Ligand Directed Delivery of Antisense Oligonucleotides in Humans: An Integrated Comparison of Parent 2'-OMethoxyethyl Chimeric ASOs to the GalNAc3-Conjugates' Monday, October 14, 5:35 p.m.– 7:30 p.m.'Controlling Chirality of Phosphorothioates in Antisense Oligonucleotides Does Not Enhance Potency or Duration of Effect in the CNS' Monday, October 14, 5:35 p.m.– 7:30 p.m.'A novel and translational role for autophagy in antisense oligonucleotide trafficking and activity'
Complete abstracts, details on presentation times and changes to presentation dates can be found on the
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for both children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.
To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-leadership-in-rna-targeted-therapeutics-recognized-at-the-oligonucleotide-therapeutics-society-annual-meeting-300936161.html
Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D., Vice President, Investor Relations, 760-603-2741; Ionis Pharmaceuticals Media Contact: Roslyn Patterson, Vice President, Corporate Communications, 760-603-2681